Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
Fuente:
FierceBiotech
Merck & Co. touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis suppurativa (HS).